{
  "docId": "019de074-ac90-73cc-861b-68f2ee02d519",
  "docSlug": "5e6566e4cd37b5a4c67661e229e01a81",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 41 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 41,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "Includes a stacked bar chart showing revenue trends by product over 7 quarters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ac90-73cc-861b-68f2ee02d519/25",
  "deckHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519",
  "deckJsonHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519.json",
  "deckAnchorHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.45,
        "y": 0.77
      },
      "kind": "callout",
      "text": "Strong commercial execution across indications and geographies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a529137-05d8-423e-95b5-7a2627a9344a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Revenue by product over time",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd7af1a2-67d9-4380-b049-bb6a24f0878c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.45,
        "y": 0.38
      },
      "kind": "list",
      "text": "Ultomiris +61% driven by successful conversion from Soliris, new patients and market expansion. Soliris (13%) decline reflecting successful conversion, partially offset by NMOSD growth. Strensiq +28% and Koselugo >2x reflecting strength of patient demand.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31ff2ae4-48dd-4305-a818-0c18c1fb084c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Includes Kanuma and Koselugo. 2. Q3 2021 Total Revenues reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021. C5 = C5 inhibitors Ultomiris and Soliris; CER = constant exchange rates; NMOSD = neuromyelitis optica spectrum disorder. Collaboration partners: Merck & Co., Inc. (Koselugo).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97b45a45-008a-47dd-862f-a509f61b5138",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Accelerated conversion in C5, continued strength beyond complement",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c2da56d-3da0-4e7b-9337-faa7755bd139",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Rare Disease – Q1 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b3d5bcb-40f5-43c3-944d-68abd3a6d8b9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "65085a95-2c38-4ee7-a364-a6a8cc62f676",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcasing progress in Oncology, BioPharmaceuticals, and Rare Disease provide satisfaction and demonstrate the company's growth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}